title: mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats.
abstract: Addiction to methamphetamine is a significant public health problem, and there are currently no pharmacological agents that are approved for the treatment of addiction to this powerful psychostimulant. Chronic methamphetamine use leads to cognitive dysfunction as well as numerous psychiatric, neurological, and cardiovascular complications. There is a growing body of literature implicating an important role for glutamate neurotransmission in psychostimulant addiction. In the present study, we examined the effects of the selective type 5 metabotropic glutamate receptor (mGluR5) antagonist 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP) on intravenous self-administration of methamphetamine and reinstatement of methamphetamine-seeking behavior. Adult male Sprague-Dawley rats were trained to respond for intravenous methamphetamine (0.1 or 0.2 mg/kg per infusion) or food pellets and were subsequently administered vehicle or MTEP (0.3-3 mg/kg) before drug or food self-administration on a fixed-ratio 1 (FR1) schedule of reinforcement or a progressive ratio (PR) schedule of reinforcement. We also examined the effects of vehicle or MTEP (0.3-3 mg/kg) on cue- and drug-induced reinstatement of methamphetamine-seeking behavior as well as cue-induced reinstatement of food-seeking behavior. Our results show that MTEP dose dependently reduced the reinforcing effects of methamphetamine under FR1 and PR schedules of reinforcement without altering overall responding for food. MTEP also dose dependently prevented cue- and drug-induced reinstatement of methamphetamine-seeking behavior, but did not alter cue-induced reinstatement of food-seeking behavior. Together, these results indicate that mGluR5 receptors mediate methamphetamine reinforcement and methamphetamine-seeking behavior, and that pharmacological inhibitors of mGluR5 receptor function may represent a novel class of potential therapeutic agents for the treatment of methamphetamine addiction.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC 29425, USA.
authors.forename: Justin T
authors.initials: JT
authors.lastname: Gass
authors.forename: Megan P H
authors.initials: MP
authors.lastname: Osborne
authors.forename: Noreen L
authors.initials: NL
authors.lastname: Watson
authors.forename: Jordan L
authors.initials: JL
authors.lastname: Brown
authors.forename: M Foster
authors.initials: MF
authors.lastname: Olive
mesh_terms: D019969:Amphetamine-Related Disorders / Q000188:drug therapy*; D000704:Analysis of Variance; D000818:Animals; D001070:Appetitive Behavior / Q000187:drug effects; D016739:Behavior, Addictive / Q000188:drug therapy*; D001522:Behavior, Animal / Q000187:drug effects; D003463:Cues; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005502:Food; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage*; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors*; D012055:Reinforcement Schedule; D012646:Self Administration; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: C472365:3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine; D018691:Excitatory Amino Acid Antagonists; D011725:Pyridines; D018094:Receptors, Metabotropic Glutamate; D013844:Thiazoles; D008694:Methamphetamine
references.citation: J Neurosci. 2003 Apr 15;23(8):3531-7
references.pmid: 12716962
references.citation: J Pharmacol Exp Ther. 2005 Apr;313(1):395-402
references.pmid: 15590770
references.citation: Behav Brain Res. 2006 Oct 2;173(1):148-52
references.pmid: 16834996
references.citation: J Pharmacol Exp Ther. 2005 Mar;312(3):1232-40
references.pmid: 15550570
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1259-69
references.pmid: 15010696
references.citation: Psychopharmacology (Berl). 2007 Jul;192(4):571-80
references.pmid: 17347848
references.citation: CNS Drug Rev. 2006 Summer;12(2):149-66
references.pmid: 16958988
references.citation: Brain Res. 2007 Mar 2;1135(1):129-35
references.pmid: 17198685
references.citation: Ann N Y Acad Sci. 2008 Oct;1139:206-11
references.pmid: 18991866
references.citation: J Med Chem. 2003 Jan 16;46(2):204-6
references.pmid: 12519057
references.citation: Neuropsychopharmacology. 2006 Apr;31(4):778-86
references.pmid: 16123768
references.citation: J Psychiatry Neurosci. 2006 Sep;31(5):301-13
references.pmid: 16951733
references.citation: Psychopharmacology (Berl). 2003 Feb;165(4):359-69
references.pmid: 12491026
references.citation: Neuroscience. 1999;93(4):1359-67
references.pmid: 10501460
references.citation: Brain Res. 1992 Oct 30;594(2):327-30
references.pmid: 1360323
references.citation: Brain Res. 1994 Apr 18;643(1-2):276-81
references.pmid: 7518327
references.citation: Psychopharmacology (Berl). 2003 May;167(3):257-64
references.pmid: 12682710
references.citation: Pharmacol Biochem Behav. 1976 Jan;4(1):73-83
references.pmid: 4819
references.citation: Drug Alcohol Rev. 2008 May;27(3):253-62
references.pmid: 18368606
references.citation: Brain Res Bull. 1997;44(3):221-7
references.pmid: 9323434
references.citation: Cochrane Database Syst Rev. 2001;(4):CD003021
references.pmid: 11687170
references.citation: Addiction. 2007 Apr;102 Suppl 1:96-106
references.pmid: 17493058
references.citation: J Med Chem. 2006 Feb 9;49(3):1080-100
references.pmid: 16451073
references.citation: Alcohol Clin Exp Res. 2008 Feb;32(2):209-21
references.pmid: 18162077
references.citation: Br J Pharmacol. 2004 Jul;142(6):991-1001
references.pmid: 15210575
references.citation: J Neural Transm Gen Sect. 1993;91(2-3):241-54
references.pmid: 8099799
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:415-8
references.pmid: 14684476
references.citation: Curr Psychiatry Rep. 2006 Oct;8(5):345-54
references.pmid: 16968614
references.citation: Neuropharmacology. 2007 Feb;52(2):263-9
references.pmid: 16963088
references.citation: Am Fam Physician. 2007 Oct 15;76(8):1169-74
references.pmid: 17990840
references.citation: Neuroscience. 2001;106(3):579-87
references.pmid: 11591458
references.citation: Eur J Pharmacol. 2005 Dec 5;526(1-3):65-76
references.pmid: 16321382
references.citation: Drug Alcohol Depend. 2006 Nov 8;85(2):142-56
references.pmid: 16697125
references.citation: Neuropharmacology. 1999 Oct;38(10):1569-76
references.pmid: 10530818
references.citation: Mayo Clin Proc. 2006 Jan;81(1):77-84
references.pmid: 16438482
references.citation: J Neurosci. 2007 Aug 22;27(34):9077-85
references.pmid: 17715344
references.citation: Synapse. 1994 Jul;17(3):203-9
references.pmid: 7974204
references.citation: Neuropharmacology. 2005;49 Suppl 1:167-78
references.pmid: 16023685
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):653-71
references.pmid: 2851859
references.citation: Mol Psychiatry. 2003 Apr;8(4):373-82
references.pmid: 12740594
references.citation: Mol Pharmacol. 2005 Feb;67(2):349-55
references.pmid: 15548766
references.citation: Addict Biol. 2000 Jul 1;5(3):325-9
references.pmid: 20575849
references.citation: Psychopharmacology (Berl). 2005 Apr;179(1):255-61
references.pmid: 15619120
references.citation: J Comp Neurol. 1995 May 8;355(3):455-69
references.pmid: 7636025
references.citation: Biochem Pharmacol. 2008 Jan 1;75(1):218-65
references.pmid: 17706608
references.citation: Addiction. 2007 Apr;102 Suppl 1:49-60
references.pmid: 17493053
references.citation: Eur J Pharmacol. 2004 Sep 19;499(1-2):121-33
references.pmid: 15363959
references.citation: Pharmacol Biochem Behav. 2000 Nov;67(3):405-9
references.pmid: 11164066
references.citation: Neurosci Lett. 1993 Nov 26;163(1):53-7
references.pmid: 8295733
references.citation: J Pharmacol Exp Ther. 2005 Nov;315(2):590-600
references.pmid: 16014750
references.citation: Ann N Y Acad Sci. 1996 Oct 31;801:315-26
references.pmid: 8959044
references.citation: Eur J Pharmacol. 2003 Jul 18;473(1):35-40
references.pmid: 12877935
references.citation: J Neurochem. 2002 Nov;83(3):645-54
references.pmid: 12390526
references.citation: Neuropsychopharmacology. 2007 Mar;32(3):710-8
references.pmid: 16794568
references.citation: Nat Neurosci. 2003 Jul;6(7):743-9
references.pmid: 12778052
references.citation: Neuropsychopharmacology. 2004 May;29(5):921-8
references.pmid: 14735132
references.citation: J Neurosci. 2001 Dec 1;21(23):9471-7
references.pmid: 11717381
references.citation: J Neurosci Methods. 1996 May;66(1):1-11
references.pmid: 8794935
references.citation: Science. 1977 Dec 16;198(4322):1182-3
references.pmid: 563103
references.citation: Nat Neurosci. 2001 Sep;4(9):873-4
references.pmid: 11528416
references.citation: Neuroscience. 2007 Jun 8;146(4):1484-94
references.pmid: 17449185
references.citation: Prog Neurobiol. 2005 Apr;75(6):406-33
references.pmid: 15955613
references.citation: J Neurosci. 2000 Aug 1;20(15):RC89
references.pmid: 10899176
references.citation: Psychopharmacology (Berl). 2006 Jan;183(4):429-38
references.pmid: 16292590
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):422-8
references.pmid: 11330336
references.citation: Brain Res. 1995 Nov 27;700(1-2):99-106
references.pmid: 8624733
references.citation: Psychopharmacology (Berl). 2007 Jan;190(1):21-9
references.pmid: 17096086
references.citation: Drug Alcohol Rev. 2008 May;27(3):229-35
references.pmid: 18368603
references.citation: Neurosci Lett. 2006 Jan 2;391(3):91-5
references.pmid: 16153770
references.citation: Eur J Pharmacol. 2001 Jun 22;422(1-3):87-90
references.pmid: 11430918
references.citation: Dialogues Clin Neurosci. 2007;9(4):389-97
references.pmid: 18286799
references.citation: Psychopharmacology (Berl). 2005 Apr;179(1):262-70
references.pmid: 15717208
references.citation: Drug Alcohol Rev. 2008 May;27(3):309-17
references.pmid: 18368613
references.citation: Trends Pharmacol Sci. 2004 May;25(5):265-72
references.pmid: 15120493
references.citation: Psychopharmacology (Berl). 1998 Oct;139(3):169-84
references.pmid: 9784071
references.citation: Harv Rev Psychiatry. 2005 May-Jun;13(3):141-54
references.pmid: 16020027